Altox

Database / Pharmaceutical impurity

Pharmaceutical impurity

Lenvatinib Impurity 39

Lenvatinib Impurity 39 is listed in the pharmaceutical impurity collection under CAS 2868-37-3. Its represented structure has formula C5H8O2 and a calculated molecular weight of 100.12 g/mol.

2D chemical structure

O O

Chemical identity

Catalog name
Lenvatinib Impurity 39
Common name
Lenvatinib Impurity 39
Chemical name
methyl cyclopropanecarboxylate
CAS
2868-37-3
SMILES
COC(=O)C1CC1
InChI
InChI=1S/C5H8O2/c1-7-5(6)4-2-3-4/h4H,2-3H2,1H3
InChIKey
PKAHQJNJPDVTDP-UHFFFAOYSA-N
Associated API
Lenvatinib

Record ID: Abe35e995eb73

Computed properties

C5H8O2 Molecular formula
100.117 g/molMolecular weight
100.0524 DaMonoisotopic exact mass
26.3 ŲTopological polar surface area
0.5694 Calculated LogP (Wildman–Crippen)
24.74 cm³/molMolar refractivity (Wildman–Crippen)
2 countHydrogen-bond acceptors
0 countHydrogen-bond donors

Descriptors are calculated from the displayed SMILES. Calculated LogP is not a measured partition coefficient or a pH-specific LogD.

Molecular descriptor profile

Descriptor radar

Mol. weight LogP TPSA HBA HBD Rotatable 25 50 75 100

Structural feature counts

0 1 2 Count H-bond acceptors H-bond donors Rotatable bonds Rings Aromatic rings Stereo centers

Element composition

C H O 0 2 4 6 8 Number of atoms

Radar scale: 0–100 percentile within 25,771 distinct represented structures in this release, using the midpoint rank for ties. Larger values indicate a higher descriptor rank, not greater safety or toxicity. Element counts include hydrogen and combine isotopes under each element.

Radar values and percentile reference
DescriptorValuePercentile
Molecular weight100.1170.81
Calculated LogP (Wildman–Crippen)0.569419.66
Topological polar surface area26.310.80
Hydrogen-bond acceptors215.92
Hydrogen-bond donors011.28
Rotatable bonds (strict)112.12

Complete molecular descriptors

PropertyCalculated valueUnit / type
Molecular formulaC5H8O2dimensionless
Molecular weight100.117g/mol
Monoisotopic exact mass100.0524Da
Topological polar surface area26.3Ų
Calculated LogP (Wildman–Crippen)0.5694dimensionless
Molar refractivity (Wildman–Crippen)24.74cm³/mol
Hydrogen-bond acceptors2count
Hydrogen-bond donors0count
Rotatable bonds (strict)1count
Heavy atoms7count
Heteroatoms2count
Rings1count
Aromatic rings0count
Aliphatic rings1count
Saturated rings1count
Aromatic heterocycles0count
Aliphatic heterocycles0count
Saturated heterocycles0count
Aromatic carbocycles0count
Aliphatic carbocycles1count
Fraction of sp³ carbon atoms0.8fraction
Formal charge0e
Disconnected components1count
Isotopically specified atoms0count
Potential atom stereocenters0count
Unspecified atom stereocenters0count
Spiro atoms0count
Bridgehead atoms0count
Labute approximate surface area42.4683Ų
Valence electrons40count
Radical electrons0count
Bertz complexity84.0809index
Balaban J2.2369index

Ring categories overlap and should not be summed. No toxicity result, PDE, HBEL or acceptable intake is inferred from these descriptors.

Toxicological services and resources for Lenvatinib Impurity 39

Qualification and safety assessment of Lenvatinib Impurity 39

Explore toxicological qualification of Lenvatinib Impurity 39 and ICH M7 mutagenic impurity assessment of Lenvatinib Impurity 39 for evaluation of this impurity in its pharmaceutical context.

Where data gaps need to be addressed, resources include read-across assessment for Lenvatinib Impurity 39 and acceptable intake and limit justification for Lenvatinib Impurity 39. The relevant approach depends on the available evidence, exposure and duration of use.

Related Altox services and technical resources

Identity sources and calculation method

Identifiers originate from the source catalogues and available public identity records. InChI and InChIKey on this page are generated from the displayed SMILES. RDKit validation checks the molecular representation; it does not independently verify every catalogue assignment.

Discuss an assessment for Lenvatinib Impurity 39

Explore Altox services and software through the Altox Pharma-Hub.